Nuvalent, Inc. (NUVL)

102.58 -2.39 (-2.28%) USD  |  NASDAQ  |  Dec 16, 16:00
102.58 0.00 (0.00%) After-Hours: 18:43
More

Nuvalent Research and Development Expense (Annual): 217.77M for Dec. 31, 2024

Research and Development Expense (Annual) Chart

View Research and Development Expense (Annual) for NUVL.
Upgrade now.
Sep '18
Jan '19
May '19
 
285.00
270.00
255.00
240.00
View Research and Development Expense (Annual) Chart
Start Trial

Historical Data

View Historical Data
Start Trial

R&D Expense Definition

View R&D Expense Definition
Start Trial

R&D expense is a line item from many companies' income statements.

Read full definition.

Research and Development Expense (Annual) Range, Past 5 Years

View Research and Development Expense (Annual) Range, Past 5 Years
Start Trial
--
Minimum
--
Maximum
--
Average
--
Median

Research and Development Expense (Annual) Benchmarks

View Research and Development Expense (Annual) Benchmarks
Start Trial
Pfizer Inc. 10.74B
Xencor, Inc. 227.69M
NovaBay Pharmaceuticals, Inc. 0.042M
Palatin Technologies, Inc. 14.90M
Theriva Biologics, Inc. 12.03M